333O - Post-transplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in diffuse large B cel...
|Date||19 December 2016|
|Event||ESMO Asia 2016 Congress|
Imaging, Diagnosis and Staging
|Citation||Annals of Oncology (2016) 27 (suppl_9): ix104-ix111. 10.1093/annonc/mdw586|
Z. Ying1, X. Wang2, Y. Zhang2, Y. Song1, W. Zheng1, X. Wang1, Y. Xie1, N. Lin1, M. Tu1, C. Zhang1, L. Ping1, W. Liu1, L. Deng1, J. Zhu1
The predictive value of 18F-FDG PET in patients with diffuse large B cell lymphoma (DLBCL) who are receiving high-dose chemotherapy and autologous stem cell transplantation (HDC-ASCT) remains a matter of debate. This study evaluated the role of 18F-FDG PET scan in patients with DLBCL before and after ASCT.
Between Nov 2010 and Dec 2014, 65 patients with diffuse large B cell lymphoma were treated with HDC-ASCT at Peking University Cancer Hospital. 48 patients underwent PET imaging either before or after ASCT. Deauville criteria (5-point scale) was used to define negative (score 1,2 or 3) or positive (score 4 or 5) PET. The impact of pre- or post-ASCT PET on predicting prognosis were retrospectively analyzed.
Median age was 43. The median follow-up time was 30.5 months. In a univariate analysis, negative pre- and post-ASCT PET was associated with better progression-free survival (PFS) and overall survival (OS) than positive pre- and post-ASCT PET (pre-ASCT PET, p = 0.007, p = 0.011; post-ASCT PET, p = 0.00, p = 0.00). Patients were also classified into four groups according to PET results before and after ASCT: those who were negative before and after (-/-; n = 26), positive before and negative after (+/-; n = 6), positive before and after (+/-; n = 8), negative before and positive after (-/+, n = 2). PFS and OS were significantly better for the -/- and +/- groups as compared with other groups (p = 0.00, p = 0.00). More importantly, there was no difference in terms of PFS and OS between the -/- group compared with +/- group. In the multivariate analysis, post-ASCT was identified as the only independent prognostic factor (PFS, p = 0.001; OS, p = 0.007).
Our study demonstrated post-ASCT PET is the main prognostic factor in patients with DLBCL.
Clinical trial indentification
Legal entity responsible for the study
Peking University Cancer Hospital IRB
Peking University Cancer Hospital
All authors have declared no conflicts of interest.